Mock inspections, documentation readiness, employee interview coaching, and real-time inspection support — from an FDA audit consultant who has guided 200+ companies through successful FDA inspections across every regulated industry.
Jared Clark, JD, MBA, PMP, CMQ-OE, RAC, CPGP, CFSQA
FDA inspection preparation is a core service of Certify Consulting, our full-service certification and compliance practice.
Every FDA-regulated company will eventually face an FDA inspection. It is not a question of if but when. The difference between companies that pass cleanly and those that receive Form 483 observations, warning letters, or worse — consent decrees and import alerts — almost always comes down to one factor: how well they prepared before the inspector arrived.
An FDA inspection is a high-stakes event. Investigators are trained to identify systemic failures in your quality system, manufacturing processes, documentation practices, and organizational culture. They look for patterns, not just isolated incidents. A single poorly handled question during an employee interview, a missing batch record, or an outdated SOP can trigger a cascade of observations that threatens your entire operation.
The companies that treat FDA inspection preparation as a continuous discipline — rather than a panic-driven exercise triggered by an inspection notice — are the ones that consistently achieve favorable outcomes. They have current documentation, trained employees, functioning CAPA systems, and leadership that understands their regulatory obligations. An experienced FDA audit consultant helps you build and maintain that level of readiness so that when the inspector does arrive, the inspection confirms what you already know about your operation rather than exposing what you do not.
“An FDA inspection should confirm what you already know — not reveal what you don’t.”
Our inspection preparation program is designed by a Regulatory Affairs Certified (RAC) and Certified Pharmaceutical GMP Professional (CPGP) consultant who has guided over 200 companies through FDA inspections across drugs, medical devices, food, and dietary supplements. We know what investigators look for, how they think, and what separates a clean inspection from an enforcement action. Our ongoing compliance management services ensure that inspection readiness becomes part of your organizational DNA — not a one-time project.
Understanding the type of inspection you are facing is critical to effective preparation. Each inspection type has a different trigger, scope, and focus. The FDA conducts thousands of inspections each year across all regulated product categories, and the approach varies significantly depending on the inspection classification.
A pre-approval inspection is triggered when your company has a pending regulatory submission with the FDA — such as a New Drug Application (NDA), Abbreviated New Drug Application (ANDA), Premarket Approval (PMA), or 510(k) notification. The FDA conducts a PAI to verify that the data in your submission is accurate, that your facility can consistently manufacture the product as described, and that your quality system is adequate to support commercial production.
PAIs are highly focused. Investigators will examine your development data, process validation records, laboratory notebooks, analytical test methods, raw material qualification, and stability data. They will compare what you submitted on paper with what actually happens on the manufacturing floor. Data integrity is the single most critical focus area during a pre-approval inspection — any discrepancy between submitted data and source records can result in application refusal.
Routine surveillance inspections are the most common type of FDA inspection. They are conducted on a periodic schedule — typically every two to three years for drug and device manufacturers, though higher-risk facilities may be inspected more frequently. These inspections evaluate your overall compliance with Current Good Manufacturing Practice (CGMP) requirements under the applicable regulations (21 CFR Parts 210/211 for drugs, 21 CFR Part 820 for devices, 21 CFR Part 111 for dietary supplements, or 21 CFR Part 117 for food under FSMA).
Routine inspections cover your entire quality system: management responsibility, document controls, production controls, CAPA, complaint handling, supplier qualification, training, and facilities and equipment. Investigators use the FDA’s Quality System Inspection Technique (QSIT) as a framework, though they have discretion to expand their focus based on what they observe during the inspection.
For-cause inspections are triggered by a specific event that raises FDA concern about your facility or products. Common triggers include consumer complaints, adverse event reports, product recalls, whistleblower allegations, or information from other federal or state agencies. For-cause inspections are typically unannounced and may be narrowly focused on the triggering issue or expanded to a comprehensive assessment if additional concerns are identified.
For-cause inspections carry elevated risk because the FDA has already identified a reason for concern. The burden of proof shifts — instead of demonstrating general compliance, you must demonstrate that the specific concern has been adequately addressed and that your quality system prevented (or will prevent) the issue from recurring. These inspections require immediate, strategic response.
After a company receives a warning letter or significant Form 483 observations, the FDA will schedule a follow-up inspection to verify that corrective actions have been implemented and are effective. These inspections are narrowly scoped to the specific deficiencies cited in the previous enforcement action — but investigators will also look for evidence that the underlying quality system has been strengthened, not just the surface-level symptoms.
Follow-up inspections are perhaps the highest-stakes inspection type. If the FDA determines that your corrective actions are inadequate, the consequences escalate rapidly — from warning letter to consent decree, injunction, product seizure, or even criminal prosecution. Our warning letter remediation services are specifically designed to prepare companies for successful follow-up inspections.
Critical timing: If you have received an FDA inspection notice (FDA Form 482) or anticipate an inspection based on a pending submission, contact us immediately. Our rapid-response preparation service can mobilize within 24 to 48 hours to assess your readiness and address critical gaps before the inspector arrives.
Understanding your rights during an FDA inspection is not about being adversarial — it is about ensuring the inspection process is fair, accurate, and properly documented. Companies that understand their rights tend to have better inspection outcomes because they can manage the process more effectively while remaining fully cooperative.
At the start of any FDA inspection, the investigator will present FDA Form 482 — Notice of Inspection. This form identifies the inspector, their credentials, and the legal authority under which they are conducting the inspection (typically Section 704 of the Federal Food, Drug, and Cosmetic Act). You should request to see the inspector’s FDA credentials and make a copy of the Form 482 for your records.
Some inspections are pre-announced (the FDA contacts you in advance to schedule), while others are unannounced (the inspector simply arrives). Pre-approval inspections are almost always pre-announced. Routine surveillance inspections may be either. For-cause inspections are typically unannounced. Regardless of whether the inspection is announced or unannounced, you are expected to provide the investigator access to your facility and records within a reasonable timeframe.
Practical tip: Assign a dedicated “back room” team during the inspection. While the escort team accompanies the inspector, the back room team locates requested documents, reviews them before they are handed over, and coordinates responses to investigator questions. This two-team approach prevents delays and ensures that every document provided has been reviewed for completeness and accuracy.
A structured, systematic approach to identifying and closing compliance gaps before the FDA does — conducted by a certified FDA audit consultant with real-world inspection experience.
We review your quality manual, SOPs, previous inspection history, regulatory submissions, complaint files, CAPA log, and organizational structure to understand your operation before setting foot on-site.
We conduct a realistic, full-scope inspection of your facility using the same QSIT methodology and questioning techniques that FDA investigators use. We examine every system the FDA would examine.
We conduct practice interviews with key personnel — quality, production, laboratory, and management — to assess how they respond under pressure and identify coaching opportunities before the real inspection.
We deliver a detailed report categorizing findings by severity: critical observations (would likely appear on a 483), major findings, and minor improvement opportunities — with specific remediation recommendations.
We help you prioritize and implement corrective actions — updating SOPs, closing CAPA items, strengthening documentation practices, and retraining staff on identified weak spots.
Before the actual inspection, we conduct a final readiness check to confirm that all critical findings have been addressed, documentation is current, and your team is prepared and confident.
Documentation is the backbone of every FDA inspection. Investigators operate under a simple principle: if it wasn’t documented, it didn’t happen. Your quality system documentation must be complete, current, accessible, and internally consistent. Documentation failures are among the most frequently cited categories of Form 483 observations across all FDA-regulated industries.
Our documentation readiness assessment evaluates every layer of your documentation hierarchy — from your quality manual and quality policy down to individual batch records, laboratory notebooks, and training logs. We verify that your documentation system meets CGMP requirements and that it will withstand the scrutiny of an FDA investigator who is trained to find inconsistencies.
Your quality manual, quality policy, and quality objectives should clearly articulate your organization’s commitment to compliance and define the structure of your quality management system. We verify that your quality manual accurately reflects your current operations — not an aspirational version that does not match what happens on the floor. Common deficiencies include outdated organizational charts, references to discontinued procedures, and quality objectives that are not measurable or tracked.
SOPs are the most commonly reviewed documents during an FDA inspection. Every regulated activity must have a written procedure, and that procedure must be followed as written. We review your SOPs for completeness, clarity, currency (are they up to date?), and consistency (do they align with your actual practices?). We also verify that your SOP revision history and change control process meet FDA expectations — including proper review and approval signatures, effective dates, and controlled distribution.
Batch production records, device history records (DHRs), or food production records must be complete, legible, and contemporaneous. We review a sample of your production records to verify that every required step is documented, that deviations are properly captured and investigated, and that the records can be traced back to raw material inputs, in-process testing, and final release decisions. Data integrity is a primary focus area — the FDA expects that all data entries are attributable, legible, contemporaneous, original, and accurate (ALCOA principles).
Your Corrective and Preventive Action (CAPA) system is one of the subsystems investigators examine most closely. We review your CAPA log to verify that investigations are thorough (root cause analysis, not just symptoms), that corrective actions are implemented within reasonable timeframes, that effectiveness checks are performed, and that trending analysis identifies systemic issues. An FDA audit consultant sees CAPA deficiencies in nearly every mock inspection — this is consistently one of the top 483 observation categories.
FDA investigators will verify that every employee performing a regulated activity has documented training on the applicable SOPs and that training is current (i.e., employees have been retrained when SOPs are revised). We review your training matrix, individual training records, and training procedures to identify gaps — including employees who may have been missed during SOP revisions or new hires whose training is incomplete.
Documentation readiness checklist: Our assessment covers your quality manual, SOPs, batch/production records, CAPA logs, complaint files, validation protocols and reports, equipment qualification and calibration records, supplier qualification files, training records, management review minutes, and internal audit reports. Every document is evaluated against the applicable CGMP regulation for your product category.
FDA investigators conduct employee interviews to verify that your written procedures match your actual practices. They interview operators, technicians, quality engineers, laboratory analysts, supervisors, and senior management. The purpose is to assess whether employees understand their responsibilities, follow established procedures, and can explain their work in a clear and consistent manner.
Employee interviews are where many inspections go wrong. Well-meaning employees can inadvertently create 483 observations by volunteering information beyond the scope of the question, speculating about processes they do not directly control, contradicting documented procedures, or expressing uncertainty about standard practices. Interview preparation is not about coaching employees to hide problems — it is about ensuring that every answer is truthful, relevant, and delivered with confidence.
Common interview topics include:
We conduct realistic practice interviews with all personnel who are likely to be interviewed during the actual inspection. Each session covers:
Interview preparation reduces risk. In our experience, companies that conduct employee interview preparation before an FDA inspection have significantly fewer 483 observations related to procedure adherence and training deficiencies. Prepared employees answer questions clearly, point investigators to the right documentation, and avoid creating unnecessary concerns.
These are the areas where FDA inspectors most frequently cite deficiencies. Our mock inspection process specifically targets each of these high-risk categories.
When the FDA inspector arrives, you do not have to face the inspection alone. Our real-time inspection support service places an experienced FDA audit consultant at your side — either on-site or on-call — throughout the entire inspection. This is not a passive observation role. Your consultant is actively advising your team, helping locate documents, coaching employees before interviews, reviewing observations in real time, and ensuring that the inspection process runs as smoothly as possible.
Do not wait until the inspector arrives. If you have received an FDA Form 482 notice or know that an inspection is imminent, contact us immediately at (858) 240-4353. We can mobilize within 24 to 48 hours for rapid-response preparation and on-site support.
Our FDA audit consulting covers inspection preparation for every type of FDA-regulated facility. Each industry has its own CGMP regulations, inspection focus areas, and common 483 categories. We tailor our mock inspection approach to your specific product category and the regulatory framework that applies to your operation.
Explore IndustriesCommon questions about FDA inspection preparation, mock inspections, and working with an FDA audit consultant.
FDA inspection preparation works best as part of a comprehensive compliance strategy. These related services strengthen your overall regulatory posture.
Strategic response development, CAPA implementation, and consent decree prevention when 483 observations escalate to warning letters.
Learn more →Ongoing compliance monitoring, quality system maintenance, and continuous inspection readiness to keep your facility audit-ready year-round.
Learn more →Facility registration, product listing, and U.S. Agent services — the regulatory foundation that supports every FDA inspection.
Learn more →Schedule a free consultation with Jared Clark, RAC. Whether you are preparing for an upcoming inspection, need a mock inspection, or want real-time support during an active inspection — we will help you achieve the outcome your business needs.